My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cellectar Biosciences, Inc. - Common Stock (NQ:CLRB)

6.100 +0.320 (+5.53%)
Streaming Delayed Price Updated: 3:10 PM EDT, Oct 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cellectar Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Synergy CHC Corp. (NASDAQ: SNYR) Restructures Debt with $20M Facility to Power Global Growth and FOCUSfactor Beverage Expansion
Via AB Newswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Stay updated with the stocks that are on the move in today's after-hours session.
As the regular session of the US market concludes on Wednesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
What's going on in today's session
Here are the top movers in Wednesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
Curious about the most active stocks on Wednesday?
Stay updated with the latest market activity on Wednesday. Explore the most active stocks in today's session and stay informed about the stocks that are in the spotlight. 
Via Chartmill
Crude Oil Falls Over 1%; ISM Services PMI Tumbles In May
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
What's Behind Cellectar Biosciences' Stock Surge? FDA Update Explained
Cellectar's Iopofosine I 131 earned FDA breakthrough therapy designation for relapsed Waldenstrom macroglobulinemia following strong trial data. 
Via Benzinga
Which stocks are experiencing notable movement on Wednesday?
Curious to know what's happening on the US markets in the middle of the day on Wednesday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
US Stocks Higher; Dollar Tree Shares Plunge After Q1 Earnings
 
Via Benzinga
Wednesday's session: gap up and gap down stocks
In today's session, there are notable price gaps in the US markets on Wednesday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Earnings Scheduled For May 13, 2025
 
Via Benzinga
Insights Ahead: Cellectar Biosciences's Quarterly Earnings
 
Via Benzinga
Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025
From Cellectar Biosciences, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Cellectar Announces Plan to Explore Strategic Alternatives
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Earnings Scheduled For March 13, 2025
 
Via Benzinga
Cellectar Biosciences to Present at the 37th Annual Roth Conference
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Thursday, March 13, 2025
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Cellectar Biosciences to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase during the JP Morgan Healthcare Conference
From Cellectar Biosciences, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Crude Oil Jumps 2%; Macy's Lowers Earnings Forecast
 
Via Benzinga
Cellectar Biosciences Stock Plunges As Cancer-Focused Cancer Firm Pursues Strategic Options
Due to FDA communications, Cellectar Biosciences will explore options for development of its cancer drug. Focus on isotopes for solid tumors. 
Via Benzinga
Nasdaq Surges Over 1%; US Inflation Rises In-Line With Expectations
 
Via Benzinga
Topics Economy
Why Stitch Fix Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring
From Cellectar Biosciences, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.